BLyS = B lymphocyte stimulator, also known as B-cell activating factor or BAFF; APRIL = A proliferation-inducing ligand; TACI = transmembrane activator and CAML interactor.
1Macpherson AJ, et al. Mucosal Immunol 2008; 2Dillon SR, et al. Arthritis Res Ther 2010; 3Gordon C, et al. Rheumatol Adv Pract 2019 and data on file.
Click below to learn why dual inhibition of BLyS/APRIL matters
While BLyS is known to bind all three receptors, its biologic effect is lessened when binding mature B-cell TACI and BCMA.
1Schneider P. Curr Opin Immunol 2005; 2Xin G, et al. J Nephrol 2013; 3Cao Y, et al. Mol Med Rep 2020; 4Zhai Y, et al. Medicine (Baltimore) 2016; 5McCarthy D, et al. J Clin Invest 2011; 6Haselmayer P, et al. Eur J Immunol 2017; 7Benson M, et al. J Immunol 2008; 8Yeh T, et al. J Allergy Clin Immunol 2020; 9Tsiantoulas et al. Nature 2021; 10Vallerskog T, et al. Arthritis Res Ther 2006.
Atacicept is uniquely able to substantially reduce Gd-IgA1, the core of the immune complexes that cause disease progression and mortality in IgAN patients.1
Click through the pathway below to learn about the roles of BLyS, APRIL, and atacicept in IgAN pathophysiology
Gd-IgA1 = galactose-deficient immunoglobulin A1.
1Wyatt RJ, et al. N Engl J Med 2013; 2Xin G, et al. J Nephrol 2013; 3Cao Y, et al. Mol Med Rep 2020; 4Zhai Y-L, et al. Medicine (Baltimore) 2016; 5Benson MJ, et al. J Immunol 2008; 6Haselmayer P, et al. Eur J Immunol 2017; 7Bagchi S, et al. PLoS One 2019; 8Zheng S, et al. JCI Insight 2020; 9Lafayette R, et al. ERA 2023 late breaking oral presentation, June 17; 10Suzuki H, et al. J Clin Invest 2009; 11Xie X, et al. J Pathol 2021; 12Barratt J, et al. ERA 2022; 13Zhang X, et al. Clin J AM Soc Nephrol 2021; 14Barratt J, et al. ASN 2022.
Multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of atacicept in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
Click each endpoint to learn more
Met primary endpoint: statistically significant proteinuria reduction with atacicept vs placebo at 24 weeks
Atacicept 150 mg vs placebo in per-protocol analysis at 36 weeks: Δ43%; p = 0.003
Gd-IgA1 reduction from baseline with atacicept 150 mg at 36 weeks
First B cell modulator to demonstrate substantial Gd-IgA1 reduction in a multinational, doubleblind placebo-controlled trial
Multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety and efficacy of atacicept 150 mg in adults with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
Currently recruiting—learn more at theORIGINiganstudy.com or clinicaltrials.gov